Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?

Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Investment Research • Sep 17, 2026

Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now

TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.

Zacks Investment Research • Sep 9, 2026

Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics

On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bionics Inc (NASDAQ:BBNX), noting that both companies are advancing initiatives to play in faster-growing segments of the insulin pump market.

Benzinga • Aug 21, 2026

Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi

Tandem Diabetes Care NASDAQ: TNDM highlighted its plans to expand insulin pump adoption through a shift to pharmacy distribution in the U.S., direct sales in additional international markets and upcoming product launches, including a tubeless version of its Tandem Mobi pump.

MarketBeat • Aug 18, 2026

TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up

Tandem Diabetes shares jump 19.1% after a narrower-than-expected Q2 loss, as higher pump shipments and a 57% gross margin offset a slight revenue miss.

Zacks Investment Research • Aug 12, 2026

Tandem Diabetes Care Q2 Earnings Call Highlights

Tandem Diabetes Care NASDAQ: TNDM reported second-quarter results that included record sales, pump shipments and gross margin for a second quarter, while management highlighted early progress in its transition to pharmacy-channel reimbursement and continued development of new insulin-delivery technologies.

MarketBeat • Aug 7, 2026

Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript

Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 7, 2026

Tandem Diabetes Care Announces Second Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights Sales of $254.6 million worldwide, including $179.3 million in the United States (U.S.) Gross margin of 57%, up 460 basis points compared to second quarter 2025 Pump shipments of more than 33,000 pumps worldwide, including 22,000 pumps in t.

Business Wire • Aug 6, 2026

Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Aug 7, 2026

Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.48 per share a year ago.

Zacks Investment Research • Aug 7, 2026